The PAH Disability and Bothersomeness Questionnaire

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-16

Study Completion Date

2018-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop a patient-reported questionnaire to investigate the impact of PAH (pulmonary arterial hypertension) on patients' daily lives in terms of bothersomeness and disability.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects

NCT03304548

Hypertension, Pulmonary

COMPLETED

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365

Pulmonary Arterial Hypertension

COMPLETED

Medication Reconciliation in Pulmonary Hypertension

NCT04744584

Pulmonary Hypertension Pulmonary Hypertension Chronic Thromboembolic Pulmonary Arterial Hypertension

COMPLETED

What is the Role of the Exposome in Pulmonary Hypertension

NCT07172334

Pulmonary Arterial Hypertension (PAH) Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NOT_YET_RECRUITING

Prospective Longitudinal Study of Patients With Idiopathic Pulmonary Arterial Hypertension, Family or Taking Anorectics

NCT01185730

Pulmonary Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A 3-steps study protocol was initiated in 2011 to develop a patient reported outcome measure (PROM) in PAH.The first two steps have been completed (qualitative study and Delphi consensus study) leading to the development of a provisional 37-items questionnaire. A reduction of items in this provisional questionnaire and the validation of the final questionnaire are the goals of the current study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension (PAH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Arterial Hypertension patients

37-items questionnaire

Intervention Type OTHER

Patient will answer the PAH-DBoQ questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

37-items questionnaire

Patient will answer the PAH-DBoQ questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with idiopathic and heritable PAH;
* patients over 18;
* male and female;
* NYHA Functional Class I, II, III \& IV;
* Written consent signed
* Patients with a good understanding of the French - language
* Patient affiliated with a social security scheme

Exclusion Criteria

* Patients under 18 years of age
* Patients with other pathologies associated with PAH (Group 1)
* Patients with other forms of pulmonary hypertension (groups 2, 3, 4 and 5)
* Non-consenting patients
* Patients who do not have a good understanding of the French language

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No